Justin Petrone covers consumer genomics, ancestry testing, and the microarray and biochip sector of the genomics market for GenomeWeb.
The Danish rare cell diagnostics company is also in the process of migrating its tests from array comparative hybridization to next-generation sequencing.
CEO and Cofounder İbrahim Çağrı Kurt discussed the new test during a presentation at Slush, an annual startup conference held in Helsinki this week.
The Spanish company last week announced that it raised €13 million in Series B financing to fund its efforts to supplant culture-based methods with molecular testing.
The institute recently decided to create a new way to evaluate new tests, called the Early Value Assessment program, which has a six-month turnaround time.
If commercialized, the assay will mark Lucira's entry into market for at-home diagnostics for sexually transmitted infections.
The Digital Innovations and Diagnostics for Infectious Diseases in Africa project kicked off this month and will run through September 2027 with a budget of about €6 million.
The envisioned labs could be used to test emerging pathogens in the field using advanced molecular technologies, such as PCR and next-generation sequencing.
Called WID-qEC, the test uses quantitative PCR methylation profiling to diagnose endometrial cancer in women presenting with symptoms.
As part of the program, point-of-care tests sold by Genedrive and Genomadix will be assessed, as well as laboratory-developed tests used within the UK National Health Service.
The partnership will see the two companies scour a Norwegian biobank for data that could produce a multitude of new aging-related tests, therapies, and perhaps companion diagnostics.